Market Cap | 35.85K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -107.44k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 15.00% |
Sales | 178.45k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -50.00% | |
Recommedations | - | Quick Ratio | 3.95 | Shares Outstanding | 1.88B | 52W Low Chg | 100.00% |
Insider Own | - | ROA | - | Shares Float | - | Beta | 53.29 |
Inst Own | - | ROE | -45.08% | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | 45.06% | Profit Margin | -60.21% | Avg. Volume | 6,508,195 | Target Price | - |
Oper. Margin | -122.25% | Earnings Date | - | Volume | 1,450,000 | Change | 0.00% |
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, coffee, skincare line, tablets, and a line of pet products. The company is based in Scottsdale, Arizona.
Cantor Fitzgerald | Neutral | Feb 3, 21 |
Cantor Fitzgerald | Neutral | Jan 29, 21 |
Benchmark | Speculative Buy | Sep 9, 20 |
Cantor Fitzgerald | Neutral | Aug 13, 20 |
Cantor Fitzgerald | Neutral | May 18, 20 |
Benchmark | Speculative Buy | Dec 19, 19 |
Cantor Fitzgerald | Neutral | Nov 8, 19 |
Benchmark | Speculative Buy | Sep 10, 19 |